Table 1

Demographic and baseline clinical characteristics of the study population

Administration scheduleTotal
Every weekEvery 2 weeks
Number of patients35641
Age in years, median (range)61 (36–77)58.5 (52–69)60 (36–77)
Gender, N (%)
 Male25 (71.4)4 (66.7)29 (70.7)
 Female10 (28.6)2 (33.3)12 (29.3)
ECOG performance status, N (%)
 021 (60)1 (16.7)22 (53.7)
 114 (40)5 (83.3)19 (46.3)
Time from diagnosis in months, median (range)*25 (3–90)41.5 (12–76)35 (3–90)
Primary tumour site, N (%)
 Colon/rectum19 (54.3)4 (66.7)23 (56.1)
 Stomach4 (11.4)4 (9.8)
 Kidney4 (11.4)1 (16.7)5 (12.2)
 Pancreas2 (5.7)2 (4.9)
 Other†6 (17.1)1 (16.7)7 (17.1)
EGFR expression (N 33)% positive cells, median (range)10 (1 – 100)
Intensity of positive cells, N (%) ‡
 1+15 (46)
  2+10 (30)
  3+7 (21)
EGFR expression— cut-off 30 % positive cells §
 < 30%22 (66.6)
  ≥ 30 %11 (33.3) 
Sum of longest diameter of target lesions in mm at study entry, median (range)¶118 (22–263)148 (124–213)128 (22–263)
Prior chemotherapy regimens, N (%)
 1–210 (28.6)2 (33.3)12 (29,3)
 3–419 (54.3)2 (33.3)21 (51.2)
 ≥56 (17.1)2 (33.3)8 (19.5)
Any prior antibody therapy, N (%)**21 (60)4 (66.7)25 (61)
 Bevacizumab15 (42.9)4 (66.7)19 (46.3)
 Cetuximab15 (42.9)15 (36.6)
 Panitumumab3 (8.6)3 (7.3)
 Pankomab3 (8.6)1 (16.7)4 (9)
  • *Date of first dose of study drug – date of initial diagnosis of the disease + 1.

  • †Other primary tumours included one each of gall bladder, head and neck, lung, oesophagus, ovary, penis and thyroid cancer.

  • ‡One missing.

  • §The cut-off is set at the 75% Tukey’s hinges, which is 30.

  • ¶Two patients had no measurable disease according to RECIST criteria.

  • **12 patients received two antibodies; 15 patients received Cetuximab plus chemotherapy.

  • ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.